Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy
Bioorganic Chemistry · 2023-07 · 136 · 106550
DOI: 10.1016/j.bioorg.2023.106550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2023-07. Verfasst von Ning Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Cancer Institute, Qingdao University, Qingdao 266071, China. Hauptthemen laut MEDLINE: Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 159 Literaturangaben.
Abstract (Originalsprache)
The drugs targeting the PD-1/PD-L1 pathway have gained abundant clinical applications for cancer immunotherapy. However, only a part of patients benefit from such immunotherapy. Thus, brilliant novel tactic to increase the response rate of patients is on the agenda. Nanocarriers, particularly the rationally designed intelligent delivery systems with controllable therapeutic agent release ability and improved tumor targeting capacity, are firmly recommended. In light of this, state-of-the-art nanocarriers that are responsive to tumor-specific microenvironments (internal stimuli, including tumor acidic microenvironment, high level of GSH and ROS, specifically upregulated enzymes) or external stimuli (e.g., light, ultrasound, radiation) and release the target immunomodulators at tumor sites feature the advantages of increased anti-tumor potency but decreased off-target toxicity. Given the fantastic past achievements and the rapid developments in this field, the future is promising. In this review, intelligent delivery platforms targeting the PD-1/PD-L1 axis are attentively appraised. Specifically, mechanisms of the action of these stimuli-responsive drug release platforms are summarized to raise some guidelines for prior PD-1/PD-L1-based nanocarrier designs. Finally, the conclusion and outlook in intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy are outlined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Cancer Institute, Qingdao University, Qingdao 266071, China.
- Moji-Nano Technology Co. Ltd., Yantai 264006, China.
- The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Cancer Institute, Qingdao University, Qingdao 266071, China. Electronic address: jianghongfei@qdu.edu.cn.
- School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences, Qingdao 266071, China; Tianjin Enterprise Key Laboratory for Application Research of Hyaluronic Acid, Tianjin 300038,…
Zitieren
APA
Liu, N., Zhang, R., Shi, Q., Jiang, H., & Zhou, Q. (2023). Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy. Bioorganic Chemistry, 136, 106550. https://doi.org/10.1016/j.bioorg.2023.106550
Vancouver
Liu N, Zhang R, Shi Q, Jiang H, Zhou Q. Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy. Bioorganic Chemistry. 2023;136:106550. doi:10.1016/j.bioorg.2023.106550
BibTeX
@article{Liu2023,
author = {Liu, Ning and Zhang, Renshuai and Shi, Qiang and Jiang, Hongfei and Zhou, Qihui},
title = {Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy},
journal = {Bioorganic Chemistry},
year = {2023},
volume = {136},
pages = {106550},
doi = {10.1016/j.bioorg.2023.106550}
}
EUVIMED